EUVIMEDEUVIMED entdecken
Crossref

1952-P: Real-World Continuous Glucose Monitoring Profiles Individuals with Prediabetes

KEVIN MILLER, EDEN M. MILLER, BENECIA JUDE JOSE, NAUNIHAL VIRDI, TIMOTHY DUNN

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1952-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von KEVIN MILLER und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: This study summarizes real-world glucose data from users with prediabetes who used a FreeStyle Libre (FSL) system 1 or 2.

Methods

We conducted a retrospective cohort study using linked FSL glucose data and Inovalon Insights claims for individuals with prediabetes. Eligible participants had continuous medical and pharmacy enrollment and a diagnosis of prediabetes based on ICD-10 code and subsequent use of FSL. Summary statistics of mean glucose, glucose CV around the median, time above 140 mg/dL and 180 mg/dL were calculated and tabulated by categories of updated glucose monitoring indicator (uGMI) from 5.0 to 7.0%. Further, those that progressed to type 2 diabetes were identified.

Results

A total of 3,046 participants were included (mean age 48.7 years) and 443 were observed progressing to type 2 diabetes, while 2,603 had only prediabetes related claims. All the CGM metrics progressively increased across uGMI groups except TA180, which did not increase above 5% until the uGMI group of 6.0-6.5%.

Conclusion

CGM metrics of individuals with prediabetes are sensitive to progressive changes in glycemic management, providing insight into early glucose patterns that may inform future research. Disclosure K. Miller: Consultant; Ended; Biolinq. Consultant; Current; Eli Lilly and Company. Speaker's Bureau; Current; Eli Lilly and Company. Consultant; Current; Novo Nordisk. Research Support; Current; Abbott. E.M. Miller: Advisory Panel; Current; Abbott. Speaker's Bureau; Current; Bayer AG, Corcept Therapeutics, Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Sanofi. B. Jude Jose: Employee; Current; Abbott Diabetes. N. Virdi: Employee; Current; Abbott Diabetes. T. Dunn: Employee; Current; Abbott Diabetes.

Zitieren

APA

MILLER, K., MILLER, E. M., JOSE, B. J., VIRDI, N., & DUNN, T. (2026). 1952-P: Real-World Continuous Glucose Monitoring Profiles Individuals with Prediabetes. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1952-p

Vancouver

MILLER K, MILLER EM, JOSE BJ, VIRDI N, DUNN T. 1952-P: Real-World Continuous Glucose Monitoring Profiles Individuals with Prediabetes. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1952-p

BibTeX
@article{MILLER2026,
  author = {MILLER, KEVIN and MILLER, EDEN M. and JOSE, BENECIA JUDE and VIRDI, NAUNIHAL and DUNN, TIMOTHY},
  title = {1952-P: Real-World Continuous Glucose Monitoring Profiles Individuals with Prediabetes},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1952-p}
}
Kostenlos starten →